iwAL 2022 | T-cell engagers and treating relapsed ALL
Bijal Shah, Elias Jabbour, Nicolas Boissel and Sabina Chiaretti
• 29 Sep 2022
In this discussion, Bijal Shah, MD, H. Lee Moffitt Cancer Center, Tampa, FL, Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discuss the use of T-cell engagers in acute lymphoblastic leukemia (ALL) and share insights into the treatment of relapsed disease. This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
